A phase I/IItrial of MYO‐029 in adult subjects with muscular dystrophy
Annals of Neurology2008Vol. 63(5), pp. 561–571
Citations Over TimeTop 1% of 2008 papers
Kathryn R. Wagner, James L. Fleckenstein, Anthony A. Amato, Richard J. Barohn, K. Bushby, Diana M. Escolar, Kevin M. Flanigan, Alan Pestronk, Rabi Tawil, Gil I. Wolfe, Michelle Eagle, Julaine Florence, Wendy King, Shree Pandya, Volker Straub, Paul Juneau, Kathleen N. Meyers, Cristina Csimma, Tracey Araujo, Robert H. Allen, Stephanie A. Parsons, John M. Wozney, Edward R. LaVallie, Jerry R. Mendell
Abstract
This trial supports the hypothesis that systemic administration of myostatin inhibitors provides an adequate safety margin for clinical studies. Further evaluation of more potent myostatin inhibitors for stimulating muscle growth in muscular dystrophy should be considered.
Related Papers
- → Interference with Myostatin/ActRIIB Signaling as a Therapeutic Strategy for Duchenne Muscular Dystrophy(2012)62 cited
- [Therapeutic strategies for muscular dystrophy by myostatin inhibition].(2006)
- [Altered expression of myostatin gene in the progressive muscular dystrophy patients].(2005)
- → Myostatin mRNA expression in patients of Duchenne muscular dystrophy(2011)
- → Progress of myostatin on duchenne muscular dystrophy(2019)